BioVie Inc. announced a registered direct offering and concurrent private placement raising approximately $4.74 million by selling nearly 3 million shares at $1.60 each and warrants exercisable at $1.70. The funds will support BioVie's clinical-stage development of drugs targeting neurological diseases like Alzheimer's and Parkinson's, including their lead candidate bezisterim. The offering closes around November 5, 2026, with proceeds aimed at working capital and general corporate purposes. This financing move supports ongoing trials and future research efforts for BioVie's innovative therapies.
BioVie Inc.'s recent capital raise of approximately $4.74 million through a registered direct offering and private placement provides context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced US health stocks, 121 advanced and 23 declined. Notable movers include Amgen (AMGN) at USD 489.98 with a 6.23% gain and a typical hold time of 73 days, Charles River Laboratories (CRL) at USD 330.01 down 6.21%, and Canopy Growth (CGC) at USD 0.75 up 6.13% with all buy orders on Pluang.
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
